|
|
|
|
Rating: Buy TRGT
74.58 %
Targacept, Inc. (TRGT) rated Buy
Leerink Swann rated Buy Catalyst Biosciences Inc. (NASDAQ: CBIO) on 09/20/2007, when the stock price was $1.27.
Since then, Catalyst Biosciences Inc. has lost 74.59% as of 08/28/2015's recent price of $0.32. If you would have followed this Leerink Swann 's recommendation on CBIO, you would have lost 74.58% of your investment in 2899 days.
Targacept
Leerink Swann Equity Research provides unique perspectives and agenda-setting healthcare recommendations for investors. Supported by industry-based intelligence and thorough market examination, our proprietary research enables our clients to make well-informed healthcare investment decisions.
Our investment perspectives are driven by proprietary insights from MEDACorp. MEDACorp's more than 25,000 network professionals work with new and/or development-stage pharmaceuticals, medical devices and biotherapeutics on a daily basis. MEDACorp's extensive knowledge of products and research enables Leerink Swann to provide growth-focused clients an expertise earned through experience.
|
|
Date/Time (ET) | Symbol | Rating | Term | Price (*) | Target |
8/14/2009 8:25 AM |
TRGT
|
Buy
|
|
1.86
|
—
|
|
Trailing Performance
as of 1/1/0001 |
1 Week |
— |
1 Month |
— |
3 Months |
— |
1 YTD |
— |
|
Date/Time (ET) | Symbol | Rating | Term | Price (*) | Target |
9/20/2007 11:25 AM |
TRGT
|
Buy
|
|
1.27
|
—
|
(*) Stock Price at the time of the recommendation.
|
|